Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.

Donghwan JeonEthan HillJena E Moseman Douglas G McNeel

Published in: Journal for immunotherapy of cancer (2024)

The combination of TLR agonists and αCTLA-4 or αLAG-3 can further improve the efficacy of a cancer vaccine, an effect not observed using αPD-1 due to activation of Tregs when αPD-1 was combined with TLR3 and TLR9 agonists. These data suggest that optimal combinations of TLR agonists and immune checkpoint blockade may improve the efficacy of human anticancer vaccines.

Keyphrases

toll like receptor
inflammatory response
nuclear factor
immune response
endothelial cells
papillary thyroid
machine learning
electronic health record
induced pluripotent stem cells